Chemomab Therapeutics Ltd. (CMMB) NASDAQ
1.74
-0.12(-6.45%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.74
-0.12(-6.45%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
20
First IPO Date
February 12, 2019
| Name | Title | Pay | Year Born |
| Adi Mor George | Co-Founder, Chief Scientific Officer, Chief Executive Officer & Executive Director | 800,000 | 1982 |
| Sigal Fattal | Chief Financial Officer | 600,000 | 1971 |
| Jack Lawler | Chief Development Officer | 728,500 | N/A |
| David Weiner | Interim Chief Medical Officer | 0 | 1965 |
| Barbara Lindheim | Consulting Vice President of Investor & Public Relations, Strategic Communications | 0 | N/A |
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.